• First safety review of the KINETIC trial by the Independent Data and Safety Monitoring Board (DSMB) results in recommendation to continue as planned
  • Kinarus receives a grant of 7.000.000 CHF from the Programme for COVID Medicines of the Swiss Federal Office of Public Health
  • Kinarus completes a reverse takeover transaction with Perfect Holding SA, with shareholders representing 95.3 % of Kinarus shares receiving newly issued shares in Perfect Holding SA (first day of listing of new shares on 3 June 2022) in exchange for a contribution in kind of their Kinarus shares
  • Kinarus is issued US Patent No. 11,285,155 covering the pharmaceutical composition of KIN001 and its use in certain types of cancers, conferring protection until at least 2037


  • Kinarus receives approval from the German regulatory authority to start a large phase 2 clinical trial (approx. 400 patients) for the treatment of hospitalized COVID-19 patients
  • Third financing from private investors as well as CHF 3.0 million convertible loan secured and used to fund the phase 2 trial of KIN001 in COVID-19 as well as the related clinical development plans
  • Kinarus prepares Scientific Advice (EMA) and pre-IND meeting (FDA) for agreement on clinical and technical development and launch strategy in Europe and the US
  • First patients dosed in phase 2 clinical trial of KIN001 for oral treatment of hospitalized COVID-19 patients


  • Kinarus generates data demonstrating potent antiviral activity of KIN001 against SARS-CoV-2
  • Kinarus capitalizes on KIN001 as a potentially effective COVID-19 therapy, with the advantage of targeting multiple facets of the disease, given the drug's antiviral, anti-inflammatory, and antifibrotic activities


  • Composition of matter patent granted in Europe (US decision pending) for KIN001
  • Second financing with private investors with proceeds used to fund the clinical development of KIN001 as well as general corporate purposes


  • Kinarus receives regulatory and ethics committee approval to launch a phase 2 clinical trial of KIN001 in wet AMD as an oral therapy complementing anti-VEGF agents with the objective to extend the duration between required injections
  • Kinarus completes a clinical protocol for a complementary phase 2 trial in idiopathic pulmonary fibrosis (IPF), ready for regulatory submission


  • Pamapimod license, KIN001 as well as corresponding data carved out from Strekin
  • Kinarus AG founded based on those assets
  • First financing round with private investors with proceeds used to support clinical development
  • Kinarus files patents for KIN001 in multiple indications


  • Strekin concludes licensing agreement with Roche, ensuring exclusive global rights for development of pamapimod, a phase 2 clinical P38 MAPK inhibitor
  • Development of KIN001, a unique small molecule therapeutic
  • Initial preclinical models for KIN001 trigger selection of disease indications for clinical development